EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Suzanne I Anjie, Krisztina B Gecse, Chiara M Meloni, Andrés Vidal-Itriago, Mark Löwenberg, Geert R D'Haens

Clinical Gastroenterology and Hepatology · 2026-01 · 24 (1) · 57-68.e5

DOI: 10.1016/j.cgh.2025.03.021 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-01. Verfasst von Suzanne I Anjie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. Electronic address: s.i.anjie@amsterdamumc.nl. Hauptthemen laut MEDLINE: Infliximab, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Intravenous (IV) infliximab (IFX) combined with an immunomodulator (combination therapy) outperforms IV IFX monotherapy in terms of clinical, endoscopic, and immunogenicity outcomes in patients with inflammatory bowel disease (IBD). With the advent of subcutaneous (SC) IFX, which is associated with higher serum drug concentrations, it is essential to assess whether SC IFX monotherapy provides similar pharmacokinetic and clinical benefits as combination therapy. METHODS: We conducted a systematic review and meta-analysis (until August 2024), of studies on patients with IBD treated with SC IFX. The primary outcome was anti-drug antibodies (ADAs) formation within 12 months (M) after starting SC IFX or after switching from IV to SC IFX. Secondary outcomes included treatment persistence, clinical efficacy, and biochemical parameters. RESULTS: Twenty-four studies (N = 3172) were included. Among patients transitioning from IV IFX induction to SC IFX, immunogenicity was more prevalent with monotherapy than combination treatment (median, 68% vs 48%; odds ratio [OR], 3.29; 95% confidence interval [CI], 1.71-6.31; P < .001). Clinical response rates at 12M were comparable, with a trend favoring combination therapy (OR, 0.73; 95% CI, 0.50-1.06; P = .10). In patients switching from IV maintenance to SC IFX, relapse rates were low (median, 12% at 6M, 11% at week 50), with stable biochemical markers. Treatment persistence was high (93% at 6M, 92% at 12M). Among patients with quiescent disease at the time of switching, 1-year relapse rates were 9% to 11%, with baseline immunogenicity predicting treatment failure. CONCLUSIONS: SC IFX monotherapy is associated with higher immunogenicity rates compared with combination therapy, particularly in new IFX starters. Although clinical response was comparable, a trend favoring combination therapy warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabInflammatory Bowel DiseasesGastrointestinal AgentsHumansDrug Therapy, CombinationTreatment OutcomeInjections, Subcutaneous

Stichwörter der Autor:innen

CT-P13ImmunogenicityInflammatory Bowel DiseaseInfliximabSubcutaneous

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. Electronic address: s.i.anjie@amsterdamumc.nl.
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Medical Library, Amsterdam UMC, Amsterdam, The Netherlands.

Zitieren

APA

Anjie, S. I., Gecse, K. B., Meloni, C. M., Vidal-Itriago, A., Löwenberg, M., & D'Haens, G. R. (2026). Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 24(1), 57-68.e5. https://doi.org/10.1016/j.cgh.2025.03.021

Vancouver

Anjie SI, Gecse KB, Meloni CM, Vidal-Itriago A, Löwenberg M, D'Haens GR. Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2026;24(1):57-68.e5. doi:10.1016/j.cgh.2025.03.021

BibTeX
@article{Anjie2026,
  author = {Anjie, Suzanne I and Gecse, Krisztina B and Meloni, Chiara M and Vidal-Itriago, Andrés and Löwenberg, Mark and D'Haens, Geert R},
  title = {Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {57--68.e5},
  doi = {10.1016/j.cgh.2025.03.021}
}
Kostenlos starten →